Amplyx raises $67M in series C

Anti-infectives company Amplyx Pharmaceuticals Inc. (San Diego, Calif.) raised $67 million in an oversubscribed series C round led by Sofinnova Ventures. Also participating were new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas Capital, and existing investors New Enterprise Associates, RiverVest Venture Partners, 3×5 RiverVest II and BioMed Ventures.

This year, Amplyx plans to begin Phase II testing of APX001 to treat invasive aspergillosis and invasive candidiasis. APX001 is a small molecule that inhibits fungal enzyme GPI-anchored wall transfer protein 1 (GWT1). It has Qualified Infectious Disease Product (QIDP) and Orphan Drug designations in the U.S. to treat multiple fungal infections. Amplyx has exclusive, worldwide rights to APX001 from Eisai Co. Ltd. (Tokyo:4523)...